相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in Healthcare Facilities: A Systematic Review and Reanalysis of Quasi-experimental Studies
Sara Tomczyk et al.
CLINICAL INFECTIOUS DISEASES (2019)
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
Wenjing Wu et al.
CLINICAL MICROBIOLOGY REVIEWS (2019)
Interplay between β-lactamases and new β-lactamase inhibitors
Karen Bush et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Chau-Chyun Sheu et al.
FRONTIERS IN MICROBIOLOGY (2019)
Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018
Kati Raisanen et al.
EUROSURVEILLANCE (2019)
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Catherine L. Tooke et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016-2017 update of the Chinese SMART study
Hui Zhang et al.
INFECTION AND DRUG RESISTANCE (2019)
Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
Alen Krajnc et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Jodie C. Hamrick et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
The 2018 Garrod Lecture: Preparing for the Black Swans of resistance
David M. Livermore
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016)
Qi Wang et al.
CLINICAL INFECTIOUS DISEASES (2018)
Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis
Han Zhong et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
An update on the management of urinary tract infections in the era of antimicrobial resistance
Mazen S. Bader et al.
POSTGRADUATE MEDICINE (2017)
Therapeutic options for carbapenem-resistant Enterobacteriaceae infections
Enrico Maria Trecarichi et al.
VIRULENCE (2017)
Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam
Yunliang Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
β-Lactams and β-Lactamase Inhibitors: An Overview
Karen Bush et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3
Richard A. Alm et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Multiplex PCR for detection of acquired carbapenemase genes
Laurent Poirel et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Emergence of NDM-1-producing Acinetobacter baumannii in China
Yan Chen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Carbapenemases:: the versatile β-lactamases
Anne Marie Queenan et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
分享论文
